Search

Your search keyword '"Van Krieken, J. Han"' showing total 7 results
Start Over Author "Van Krieken, J. Han" Journal blood
7 results on '"Van Krieken, J. Han"'

1. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Xu-Monette, Zijun Y., Møller, Michael B., Tzankov, Alexander, Montes-Moreno, Santiago, Hu, Wenwei, Manyam, Ganiraju C., Kristensen, Louise, Fan, Lei, Visco, Carlo, Dybkær, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Wu, Lin, Zhao, Xiaoying, Bueso-Ramos, Carlos E., Wang, Sa A., Go, Ronald S., Li, Yong, Winter, Jane N., Piris, Miguel A., Medeiros, L. Jeffrey, and Young, Ken H.

Published
2013
Full Text
View/download PDF

2. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Author

Hu, Shimin, Xu-Monette, Zijun Y., Tzankov, Alexander, Green, Tina, Wu, Lin, Balasubramanyam, Aarthi, Liu, Wei-min, Visco, Carlo, Li, Yong, Miranda, Roberto N., Montes-Moreno, Santiago, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Zhou, Fan, Slack, Graham W., Gascoyne, Randy D., Tu, Meifeng, Variakojis, Daina, Chen, Weina, Go, Ronald S., Piris, Miguel A., Møller, Michael B., Medeiros, L. Jeffrey, and Young, Ken H.

Published
2013
Full Text
View/download PDF

3. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Author

Xu-Monette, Zijun Y., Wu, Lin, Visco, Carlo, Tai, Yu Chuan, Tzankov, Alexander, Liu, Wei-min, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Zhao, X. Frank, Choi, William W.L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Zhou, Fan, Kahl, Brad S., Winter, Jane N., Xu, Wei, Li, Jianyong, Go, Ronald S., Li, Yong, Piris, Miguel A., Møller, Michael B., Miranda, Roberto N., Abruzzo, Lynne V., Medeiros, L. Jeffrey, and Young, Ken H.

Published
2012
Full Text
View/download PDF

4. High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

Author

Elfrink, Suraya, de Winde, Charlotte M., van den Brand, Michiel, Berendsen, Madeleine, Roemer, Margaretha G.M., Arnold, Frank, Janssen, Luuk, van der Schaaf, Alie, Jansen, Erik, Groenen, Patricia J.T.A., Eijkelenboom, Astrid, Stevens, Wendy, Hess, Corine J., van Krieken, J. Han, Vermaat, Joost S.P., Cleven, Arjen H.G., de Groen, Ruben A.L., Neviani, Viviana, de Jong, Daphne, van Deventer, Sjoerd, Scheijen, Blanca, and van Spriel, Annemiek B.

Published
2019
Full Text
View/download PDF

5. High frequency of inactivating tetraspanin CD37mutations in diffuse large B-cell lymphoma at immune-privileged sites

Author

Elfrink, Suraya, de Winde, Charlotte M., van den Brand, Michiel, Berendsen, Madeleine, Roemer, Margaretha G.M., Arnold, Frank, Janssen, Luuk, van der Schaaf, Alie, Jansen, Erik, Groenen, Patricia J.T.A., Eijkelenboom, Astrid, Stevens, Wendy, Hess, Corine J., van Krieken, J. Han, Vermaat, Joost S.P., Cleven, Arjen H.G., de Groen, Ruben A.L., Neviani, Viviana, de Jong, Daphne, van Deventer, Sjoerd, Scheijen, Blanca, and van Spriel, Annemiek B.

Abstract

Tetraspanin CD37 is predominantly expressed on the cell surface of mature B lymphocytes and is currently being studied as novel therapeutic target for B-cell lymphoma. Recently, we demonstrated that loss of CD37 induces spontaneous B-cell lymphoma in Cd37-knockout mice and correlates with inferior survival in patients with diffuse large B-cell lymphoma (DLBCL). Here, CD37mutation analysis was performed in a cohort of 137 primary DLBCL samples, including 44 primary immune-privileged site-associated DLBCL (IP-DLBCL) samples originating in the testis or central nervous system. CD37mutations were exclusively identified in IP-DLBCL cases (10/44, 23%) but absent in non-IP-DLBCL cases. The aberrations included 10 missense mutations, 1 deletion, and 3 splice-site CD37mutations. Modeling and functional analysis of CD37missense mutations revealed loss of function by impaired CD37 protein expression at the plasma membrane of human lymphoma B cells. This study provides novel insight into the molecular pathogenesis of IP-DLBCL and indicates that anti-CD37 therapies will be more beneficial for DLBCL patients without CD37mutations.

Published
2019
Full Text
View/download PDF

6. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Author

Shimin Hu, Xu-Monette, Zijun Y., Balasubramanyam, Aarthi, Manyam, Ganiraju C., Visco, Carlo, Tzankov, Alexander, Wei-min Liu, Miranda, Roberto N., Li Zhang, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Youli Zu, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., van Krieken, J. Han, and Qin Huang

Subjects
*CD30 antigen, *B cells, *LYMPHOMAS, *GENE expression, *RITUXIMAB, *B cell receptors, *GENETICS, *DISEASES
Abstract

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ~14% of DLBCL patients. Patients with CD30+ DLBCL had superior 5-year overall survival (CD30+, 79% vs CD30-, 59%; P = .001) and progression-free - survival (P = .003). The favorable outcome of CD30 expression was maintained in born the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30+ DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30+ DLBCL as a distinct subgroup of DLBCL. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

7. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Author

Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, and Young KH

Subjects
3' Untranslated Regions genetics, 5' Untranslated Regions genetics, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Genetic Testing, Germ-Line Mutation genetics, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse mortality, MicroRNAs genetics, Polymorphism, Single Nucleotide, Prednisone therapeutic use, Prognosis, Retrospective Studies, Rituximab, Vincristine therapeutic use, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse genetics, Tumor Suppressor Protein p53 genetics
Abstract

We identified multiple single nucleotide variants (SNVs) in the TP53 3' untranslated region (3'UTR) in tumor specimens from 244 patients with diffuse large B-cell lymphoma (DLBCL). Patients carrying a wild-type TP53 coding sequence (CDS) and 1 or more 3'UTR SNVs had a better 5-year survival rate than patients carrying a wild-type CDS and the reference 3'UTR, yet there is no statistically significance difference in overall survival (OS). In contrast, 3'UTR variation predicted poorer OS for patients with a mutant TP53 CDS. We then sequenced TP53 3'UTR in 247 additional DLBCL patients as a validation set. Altogether, we identified 187 novel SNVs; 36 occurred at least twice. Most of the newly identified 3'UTR SNVs were located at sites that are complementary to seed sequences of microRNAs (miRNAs) that are predicted or experimentally known to target TP53. Three SNVs disrupt the seed match between miR-125b and the TP53 3'UTR, thereby impeding suppression of p53 by this miRNA. In addition, a germline SNV (rs78378222) located in the TP53 polyadenylation signal resulted in downregulation of both p53 messenger RNA and protein levels and reduction of cellular apoptosis. This study is the first to demonstrate the prognostic value of the TP53 3'UTR in cancer.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results